FDA Requests Additional Trial On Pain Drug
the Clinical Pain Advisor take:
In the release, AcelRx officials noted that late last week they received correspondence from the
In the statement, AcelRx officials noted they plan to meet with the
Company officials noted that as a result of this communication "and the need for clarity with
Zalviso would allow hospital patients with moderate-to-severe acute pain to self-dose with sublingual sufentanil tablets to manage their pain.
AcelRx will not be making the Zalviso NDA resubmission this quarter.